| Поле DC | Значение | Язык |
|---|
| dc.contributor.author | Kolesnichenko, P. D. | - |
| dc.contributor.author | Popova, I. A. | - |
| dc.contributor.author | Sheblykin, D. V. | - |
| dc.contributor.author | Alhamzah Muhi Aldeen Azeez | - |
| dc.contributor.author | Soldatov, V. O. | - |
| dc.contributor.author | Lazareva, G. A. | - |
| dc.contributor.author | Stepchenko, A. A. | - |
| dc.date.accessioned | 2020-05-27T14:00:49Z | - |
| dc.date.available | 2020-05-27T14:00:49Z | - |
| dc.date.issued | 2019 | - |
| dc.identifier.citation | Carbamylated darbepoetin in combination with ethoxydol attenuates doxorubicin-induced cardiomyopathy in rats / P.D. Kolesnichenko, I.A. Popova, D.V. Sheblykin [et al.] // EurAsian Journal of BioSciences. - 2019. - Vol.13, №2.-P. 957-963. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/30823 | - |
| dc.description.abstract | Doxorubicin is the drug of choice in the treatment of many malignant neoplasms, but its use is limited due to the risk of developing severe cardiomyopathy. This problem necessitates the prevention, early diagnosis and treatment of cardiomyopathy | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | Doxorubicin | ru |
| dc.subject | carbamylated darbepoetin | ru |
| dc.subject | ethoxydol | ru |
| dc.subject | myocardial contractility | ru |
| dc.subject | cardiomyopathy | ru |
| dc.subject | cardioprotective effect | ru |
| dc.title | Carbamylated darbepoetin in combination with ethoxydol attenuates doxorubicin-induced cardiomyopathy in rats | ru |
| dc.type | Article | ru |
| Располагается в коллекциях: | Статьи из периодических изданий и сборников (на иностранных языках) = Articles from periodicals and collections (in foreign languages)
|
